What does Linicor do?

Linicor is a healthcare practice in Damme. Public Limited, started on 4 July 2000, 1 establishment.

What is the address of Linicor?

The registered office of Linicor is located at Dorpsstraat 106, 8340 Damme.

Is Linicor still active?

Yes. According to the CBE (29 October 2026) Linicor is active, legal situation “Normale toestand”, started on 4 July 2000.

Is Linicor registered on Peppol?

Yes, Linicor is registered on the Peppol network with ID 0208:0472282607.

What is the enterprise number of Linicor?

The enterprise number of Linicor is BE0472282607.

When was Linicor founded?

Linicor was founded on 4 July 2000.

Who are the directors of Linicor?

According to the 2025 annual accounts, the directors of Linicor are: Pauline Cordonnier, LABOTOXICO NV.

Is Linicor a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 4 July 2000; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did Linicor make in 2025?

Linicor posted a profit after taxes of € 119,436 in financial year 2025.

What is the revenue of Linicor?

As a small company, Linicor is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 213,053.

Linicor (Public Limited) - Damme - BE0472282607

Dossier Linicor, printed on 29 October 2026 from databakkes.be/en/0472282607/linicor. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Linicor from Damme, company number BE0472282607, closed financial year 2025 with a result of € 119,436 after tax. For that financial year Linicor recorded a gross margin of € 213,053 and equity of € 407,113. Compared with financial year 2024, the result moved from € 75,202 to € 119,436. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Growing

€ 407,113

▲ 42% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 119,436

▲ 59% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 70,700

▼ 27% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 345,113.

People and assets in 2025

Vehicles and equipment

€ 1,399

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 416,701

▼ 19% vs 2024

€ 93,880 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 1,653

▲ 24% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 19,174

▲ € 15,423 vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 43,331 Gross margin 2022: € 43,331 First fiscal year in the series	€ 174,199 Gross margin 2023: € 174,199 ▲ € 130,868 vs 2022 (€ 43,331) Favourable step	€ 150,700 Gross margin 2024: € 150,700 ▼ 13% vs 2023 (€ 174,199) Unfavourable step	€ 213,053 Gross margin 2025: € 213,053 ▲ 41% vs 2024 (€ 150,700) Favourable step	▲ 41%
Profit after taxes	€ 1,636 Profit after taxes 2022: € 1,636 First fiscal year in the series	€ 90,123 Profit after taxes 2023: € 90,123 ▲ € 88,487 vs 2022 (€ 1,636) Favourable step	€ 75,202 Profit after taxes 2024: € 75,202 ▼ 17% vs 2023 (€ 90,123) Unfavourable step	€ 119,436 Profit after taxes 2025: € 119,436 ▲ 59% vs 2024 (€ 75,202) Favourable step	▲ 59%
Equity	€ 187,715 Equity 2022: € 187,715 First fiscal year in the series	€ 277,839 Equity 2023: € 277,839 ▲ 48% vs 2022 (€ 187,715) Favourable step	€ 287,677 Equity 2024: € 287,677 ▲ 4% vs 2023 (€ 277,839) Favourable step	€ 407,113 Equity 2025: € 407,113 ▲ 42% vs 2024 (€ 287,677) Favourable step	▲ 42%
Total debts	€ 746,524 Total debts 2022: € 746,524 First fiscal year in the series	€ 712,467 Total debts 2023: € 712,467 ▼ 5% vs 2022 (€ 746,524) Favourable step	€ 702,113 Total debts 2024: € 702,113 ▼ 1% vs 2023 (€ 712,467) Favourable step	€ 624,540 Total debts 2025: € 624,540 ▼ 11% vs 2024 (€ 702,113) Favourable step	▼ 11%
Cash	€ 37,419 Cash 2022: € 37,419 First fiscal year in the series	€ 76,262 Cash 2023: € 76,262 ▲ 104% vs 2022 (€ 37,419) Favourable step	€ 97,304 Cash 2024: € 97,304 ▲ 28% vs 2023 (€ 76,262) Favourable step	€ 70,700 Cash 2025: € 70,700 ▼ 27% vs 2024 (€ 97,304) Unfavourable step	▼ 27%
Retained profit	€ 125,715 Retained profit 2022: € 125,715 First fiscal year in the series	€ 215,839 Retained profit 2023: € 215,839 ▲ 72% vs 2022 (€ 125,715) Favourable step	€ 225,677 Retained profit 2024: € 225,677 ▲ 5% vs 2023 (€ 215,839) Favourable step	€ 345,113 Retained profit 2025: € 345,113 ▲ 53% vs 2024 (€ 225,677) Favourable step	▲ 53%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 65,363 Dividend 2024: € 65,363 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 65,363) Unchanged	▼ 100%
Bank debt	€ 646,722 Bank debt 2022: € 646,722 First fiscal year in the series	€ 580,229 Bank debt 2023: € 580,229 ▼ 10% vs 2022 (€ 646,722) Favourable step	€ 511,962 Bank debt 2024: € 511,962 ▼ 12% vs 2023 (€ 580,229) Favourable step	€ 416,701 Bank debt 2025: € 416,701 ▼ 19% vs 2024 (€ 511,962) Favourable step	▼ 19%
Balance sheet total	€ 1,434,239 Balance sheet total 2022: € 1,434,239 First fiscal year in the series	€ 1,488,175 Balance sheet total 2023: € 1,488,175 ▲ 4% vs 2022 (€ 1,434,239) Unchanged	€ 1,485,548 Balance sheet total 2024: € 1,485,548 Unchanged (€ 1,488,175) Unchanged	€ 1,525,318 Balance sheet total 2025: € 1,525,318 ▲ 3% vs 2024 (€ 1,485,548) Unchanged	▲ 3%

Key figures of Linicor, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Linicor?

What happened at Linicor in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2029 Pauline Cordonnier stepped down as director. NBB
2029 LABOTOXICO NV stepped down as director. NBB
Aug 31, 2026 New annual accounts for financial year 2025: profit of € 119,436 (▲ 59% vs 2024). filed late Source: NBB ↗
2018 Pauline Cordonnier became a director. NBB
2018 LABOTOXICO NV became a director. NBB
Nov 13, 2000 New establishment in Damme. KBO
Jul 4, 2000 Start of the company according to the CBE. KBO

In short

From € 1,636 profit in 2022 to € 119,436 profit in 2025.

Paid € 115,606 in corporate taxes since 2022.

Best year ever: 2025, with € 119,436 profit.

Paid out € 65,363 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Linicor

APOTHEKER A. LEENESONNE 92%

It owns 92% of APOTHEKER A. LEENESONNE itself.

Directors

According to the 2025 annual accounts

Pauline Cordonnier

Managing director

since 2018 · until 2029

LABOTOXICO NV

Director · represented by Jan Cordonnier

since 2018 · until 2029

Establishments

Establishment units

Physical locations of this company

Registered office

Dorpsstraat 106

8340 Damme

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.

All companies at this address →

BIOCONTROL

€ 15,161 gross margin · 2024

Apotheek Leenesonne same network

€ 595,872 gross margin · 2025

APOCHEM

€ 89,423 gross margin · 2024

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0472.282.607

VAT number

BE 0472.282.607

Registered office

Dorpsstraat 106, 8340 Damme

Names & denominations

Linicor

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

4 July 2000

Peppol

Active · Active since 21 Oct 2026

Activities · NACE

Activiteiten van bloedtransfusiecentra, bloedbanken, spermabanken, organenbanken en dergelijke

Technische testen en analyses

Activiteiten van bloedtransfusiecentra en bloed- en organenbanken

Detailhandel in farmaceutische producten

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Organisatie van congressen en beurzen

Overige technische testen en toetsen

Overige persoonlijke diensten

View on CBE Public ↗ Annual accounts (NBB) ↗

Linicor

Financials

What happened to Linicor?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions